Organizational Unit:
School of Public Policy

Research Organization Registry ID
Description
Previous Names
Parent Organization
Parent Organization
Includes Organization(s)

Publication Search Results

Now showing 1 - 10 of 23
  • Item
    Communicable diseases are not communicable
    (Georgia Institute of Technology, 2020-10) Kostoff, Ronald N. ; Briggs, Michael B. ; Kanduc, Darja ; Porter, Alan L. ; Buchtel, Henry A.
    Communicable disease is a misnomer. The disease is not communicable; the microbe mainly associated with the disease is communicable. Whether the recipient of the microbe develops the disease depends on the health of the recipient’s immune system. Our model of COVID-19 development starts with real-life exposures to multiple toxic stressors degrading the immune system. This is followed by the SARS-CoV-2 virus exploiting the degraded immune system to trigger a chain of events ultimately leading to COVID-19. To prevent or treat infectious disease, the health of the immune system must be maintained or improved. One major component of maintaining and improving immune system health is removal of those factors that contribute to immune system degradation. A previous monograph identified many factors that contribute to immune system degradation (Contributing Factors (CFs)). It was hypothesized that many of these CFs to immune system degradation were identical to those that past studies have shown were CFs to chronic diseases. To test this hypothesis, a proof-of-principle demonstration was performed to identify the commonality between CFs to immune system degradation and CFs to Parkinson’s Disease (PD). A very streamlined approach was used, and approximately 500 CFs were found in common between the two diseases. Since COVID-19 (and other infectious diseases) results from immune system degradation in our model, this means COVID-19 and PD are enabled by many of the same toxic exposures and toxic behaviors. Thus, many of the measures required to strategically treat and prevent infectious diseases are similar to those required to strategically treat and prevent chronic diseases. This is a major paradigm shift for orthodox Western medicine, but is required to achieve major advances in global population health.
  • Item
    COVID-19: Preventing Future Pandemics
    (Georgia Institute of Technology, 2020) Kostoff, Ronald N. ; Briggs, Michael B. ; Porter, Alan L.
    The COVID-19 pandemic has had global health and economic adverse impacts. The main measures being taken to control the spread of SARS-CoV-2 (the virus associated with COVID-19) are conceptually those that were taken to control the spread of SARS-CoV in the previous coronavirus-driven pandemic of 2002-2003: good hygiene, facemasks, and quarantine (lockdown). The difference is the larger scale of these measures for SARS-CoV-2. A weakened immune system appears to be the main determinant of serious/fatal reaction to viral infection (for COVID-19, SARS, and influenza alike). There are four major approaches being employed or considered presently to augment or strengthen the immune system, in order to reduce adverse effects of viral exposure. The three approaches that are mainly focused on augmenting the immune system are based on the concept that pandemics can be controlled/prevented while maintaining the immune-weakening lifestyles followed by much of the global population. The fourth approach is based on identifying and introducing measures aimed at strengthening the immune system intrinsically in order to minimize future pandemics. The four measures are: 1) restricting exposure to virus; 2) providing reactive/tactical treatments to reduce viral load; 3) developing vaccines to prevent, or at least attenuate, the infection; 4) strengthening the immune system intrinsically, by a) identifying those factors that contribute to weakening the immune system, then eliminating/reducing them as comprehensively, thoroughly, and rapidly as possible and b) replacing the eliminated factors with immune-strengthening factors. The present monograph focuses mainly on strengthening the immune system intrinsically. It identifies hundreds of factors that contribute to weakening the immune system, as well as measures that can strengthen the immune system. It also addresses the vaccine issue, since vaccine development has been emphasized in myriad forums. Potential mid-and long-term adverse vaccine effects that cannot be identified in short-term tests characteristic of efficacy testing are identified. To ensure safety, long-term testing under real-life conditions (exposures to multiple toxic stimuli) are required. There is an incompatibility between the accelerated vaccine development times being pursued by government and industry and the long times required for validation of vaccine safety. In summary, 1) there is not unanimity within the medical community for continuing post-lockdown the severe restrictions on activities of the vast majority of the total population that are mainly applicable to the most vulnerable very small minority of the total population; 2) repurposed (mainly) antiviral treatments can only be expected to have very limited results in controlling SARS-CoV-2 viral load of the most severely impacted, based on trials conducted so far; 3) it is difficult to see how safe COVID-19 vaccines can be developed and fully tested on time scales of one or two years, as proposed presently; 4) the only real protection against a future COVID-19 pandemic or any other viral pandemic is the one that was demonstrated to work in the SARS pandemic, the MERS pandemic, the COVID-19 pandemic, and in the annual influenza pandemics: a healthy immune system capable of neutralizing incoming viruses as Nature intended. We need an Operation Warp Speed (currently working to produce a vaccine in a record short time period in the USA) to identify and eliminate those factors that weaken the immune system as thoroughly, comprehensively, and rapidly as possible.
  • Item
    COVID-19 Vaccine Safety Considerations
    (Georgia Institute of Technology, 2020) Kostoff, Ronald N. ; Kanduc, Darja ; Porter, Alan L. ; Shoenfeld, Yehuda ; Briggs, Michael B.
    The SARS-CoV-2 pandemic has produced global health and economic adverse impacts. The main measures being taken to control the spread of SARS-CoV-2 and of the virus-associated diseases (COVID-19) are conceptually those that were taken to control the spread of SARS-CoV in the previous coronavirus-driven pandemic of 2002-2003: good hygiene, facemasks, and quarantine (lockdown). The difference is the larger scale of these measures for SARS-CoV-2. A degraded/dysfunctional immune system appears to be the main determinant of serious/fatal reaction to viral infection (for COVID-19, SARS, and influenza alike). There are four major approaches being employed or considered presently to augment or strengthen the immune system, in order to reduce adverse effects of viral exposure. The three approaches that are focused mainly on augmenting the immune system are based on the concept that pandemics can be controlled/prevented while maintaining the immune-degrading lifestyles followed by much of the global population. The fourth approach is based on identifying and introducing measures aimed at strengthening the immune system intrinsically in order to minimize future pandemics. Specifically, the four measures are: 1) restricting exposure to virus; 2) providing reactive/tactical treatments to reduce viral load; 3) developing vaccines to prevent, or at least attenuate, the infection; 4) strengthening the immune system intrinsically, by a) identifying those factors that contribute to degrading the immune system, then eliminating/reducing them as comprehensively, thoroughly, and rapidly as possible, and b) replacing the eliminated factors with immune-strengthening factors. A previous monograph [1] focused mainly on strengthening the immune system intrinsically, and secondarily on vaccine-related issues. It identified many hundreds of factors that contribute to weakening the immune system, as well as measures that can strengthen it. The present monograph focuses on vaccine safety. A future COVID-19 vaccine appears to be the treatment of choice at the national/international level globally. Vaccine development has been accelerated to achieve this goal in the relatively near-term, and questions have arisen whether vaccine safety has been/is being/will be compromised in pursuit of a shortened vaccine development time. In addition to identifying short-term adverse vaccine effects, the present monograph identifies potential mid-and long-term adverse vaccine effects that cannot be identified in short-term tests characteristic of vaccine efficacy testing. To ensure vaccine safety, long-term testing under real-life conditions (exposures to multiple toxic stimuli) is required. There is an incompatibility between the accelerated vaccine development times being pursued by government and industry and the long times required for validation of vaccine safety. In summary, it is difficult to see how safe COVID-19 vaccines can be developed and fully tested for safety on development time scales of one or two years, as proposed presently. The only real protection against a future COVID-19 pandemic or any other viral pandemic is the one that was demonstrated to work in the SARS, MERS, and COVID-19 pandemic, and in the annual influenza pandemics: a healthy immune system capable of neutralizing incoming viruses as nature intended.
  • Item
    Prevention and reversal of Alzheimer's disease: treatment protocol
    (Georgia Institute of Technology, 2018-01-23) Kostoff, Ronald N. ; Porter, Alan L. ; Buchtel, Henry A.
    This monograph presents a five-step treatment protocol to prevent and reverse Alzheimer's Disease (AD), based on the following systemic medical principle: at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective. The five treatment protocol steps are as follows: Step 1 - obtain a detailed medical and habit/exposure history from the patient; Step 2 - administer written and clinical performance and behavioral tests to assess the severity of the higher-level symptoms and degradation of executive functions; Step 3 - administer laboratory tests (blood, urine, imaging, etc.); Step 4 - eliminate ongoing AD contributing factors; Step 5 - implement AD treatments. This individually-tailored AD treatment protocol can be implemented with the data available in the biomedical literature presently. Additionally, while the methodology developed for this study was applied to AD, it is general and applicable to any chronic disease that, like AD, has an associated substantial research literature. Thus, the protocol and methodology we have developed to prevent or reverse AD can be used to prevent or reverse any chronic disease (with the possible exceptions of individuals with strong genetic predispositions to the disease in question or who have suffered irreversible damage from the disease).***NOTE***There are four files in this record. Presently, they are located in the left column of this Web page listed under the heading View/Open. MONOGRAPH_FINAL.pdf contains the monograph narrative; FIGURES_FINAL.xlsx contains the figures from the monograph in Excel spreadsheet format; SUPPLEMENTARY_FINAL.pdf contains supplementary bibliography and queries; and README.pdf is the ReadMe file. The two data files are referenced in the monograph as either "(see file FIGURES_FINAL.xlsx)" or "(see file SUPPLEMENTARY_FINAL.pdf)".
  • Item
    Supplemental Materials to “Emergence Scoring to Identify Frontier R&D Topics and Key Players”
    (Georgia Institute of Technology, 2018) Porter, Alan L. ; Garner, Jon ; Carley, Stephen ; Newman, Nils
    Supplemental Materials to the article on "Emergence Scoring to Identify Frontier R&D Topics and Key Players"
  • Item
    Prevention and Reversal of Alzheimer's Disease
    (Georgia Institute of Technology, 2017) Kostoff, Ronald N. ; Zhang, Yi ; Ma, Jing ; Porter, Alan L. ; Buchtel, H.A.
    This monograph identifies the full spectrum of hundreds of actionable Alzheimer's Disease (AD) contributing factors, covering the broad categories of Lifestyle, Iatrogenic, Biotoxic, Environmental/Occupational, and Psychosocial/Socioeconomic. Eliminating or reducing these actionable contributing factors offers the promise of potentially preventing and reversing AD in selected cases, and also offers the promise of dramatically lowering AD healthcare costs by circumventing the need for 1) expensive high technology AD diagnostics and treatments and 2) expensive extended maintenance and care of individuals with AD. The monograph also describes the text mining/information technology advances that allowed the AD actionable contributing factors to be identified and extracted efficiently from the large numbers of biomedical journal articles retrieved.
  • Item
    Lessons from Ten Years of Nanotechnology Bibliometric Analysis
    (Georgia Institute of Technology, 2016-09) Youtie, Jan ; Porter, Alan L. ; Shapira, Philip ; Newman, Nils
    This paper summarizes the 10-year experiences of the Program in Science, Technology, and Innovation Policy (STIP) at Georgia Institute of Technology (Georgia Tech) in support of the Center for Nanotechnology in Society at Arizona State University (CNS-ASU) in understanding, characterizing, and conveying the development of nanotechnology research and application. This work was labeled “Research and Innovation Systems Assessment” or (RISA) by CNS-ASU. RISA concentrates on identifying and documenting quantifiable aspects of nanotechnology, including academic, commercial/industrial, and government nanoscience and nanotechnology (nanotechnologies) activity, research, and projects. RISA at CNS-ASU engaged in the first systematic attempt of its kind to define, characterize, and track a field of science and technology. A key element to RISA was the creation of a replicable approach to bibliometrically defining nanotechnology. Researchers in STIP, and beyond, could then query the resulting datasets to address topical areas ranging from basic country and regional concentrations of publications and patents, to findings about social science literature, environmental, health, and safety research and usage, to study corporate entry into nanotechnology, and to explore application areas as special interests arose. Key features of the success of the program include:  Having access to “large-scale” R&D abstract datasets  Analytical software  A portfolio that balances innovative long-term projects, such as webscraping to understand nanotechnology developments in small and medium-sized companies, with research characterizing the emergence of nanotechnology that more readily produces articles  Relationships with diverse networks of scholars and companies working in the nanotechnology science and social science domains  An influx of visiting researchers  A strong core of students with social science, as well as some programming background  A well-equipped facility and management by the principals through weekly problem-solving meetings, mini-deadlines, and the production journal articles rather than thick final reports.
  • Item
    How Multidisciplinary are the Multidisciplinary Journals Science and Nature?
    (Georgia Institute of Technology, 2016-03-15) Solomon, Gregg E. A. ; Carley, Stephen ; Porter, Alan L.
    This dataset provides Integration and Diffusion scores for the articles analyzed in our study, along with correlation coefficients and descriptive statistics for the same.
  • Item
    Organizing a Multidisciplinary Workshop for Forecasting Innovation Pathways: the Case of Nano-Enabled Biosensors
    (Georgia Institute of Technology, 2011-09-17) Guo, Ying ; Huang, Lu ; Porter, Alan L. ; Robinson, Douglas K.R. ; Youtie, Jan ; Zhu, Donghua
    This paper reflects on attributes of a workshop on biosensor innovation pathways. Workshop visuals showing multiple interconnections resonated less with the scientist participants than those presenting more linear and business oriented information. Workshop discussions suggested two innovation pathways for biosensors, one involving passive use of nanomaterials in biorecognition and the other involving active use of nanomaterials in signal transduction.
  • Item
    The Use of IDR Metrics to Chart Research Trajectories at the Micro Level
    (Georgia Institute of Technology, 2011-09-17) Campbell, Audrey ; Carley, Stephen ; Porter, Alan L.
    This work focuses on two laboratories to understand the extent to which interdisciplinary research (IDR) metrics reflect research behaviors. The results indicate a statistically significant relationship between the level of interdisciplinarity and the years of active research for both the laboratories. Both laboratories evidence a tendency to become more integrative over time.